Company: PAII-WT
Filing Date: 2025-05-29
Form Type: DRS
Source: 0001213900-25-049013
Chunk: 330

Company: Pyrophyte Acquisition Corp. II
Filing Date: 2025-05-29
Form: DRS
Chunk 330
---
 considered comparable to our company. We cannot assure you, however, that the price at which the units, Class A ordinary shares or warrants will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in our units, Class A ordinary shares or warrants will develop and continue after this offering. We expect our units will be listed on the NYSE under the symbol “PAII.U” commencing on or promptly after the date of this prospectus. We expect that, once the Class A ordinary shares and warrants comprising the units begin separate trading, our Class A ordinary shares and warrants will be listed on the NYSE under the symbols “PAII” and “PAII WS,” respectively. The following table shows the underwriting discounts and commissions that we are to pay to the underwriters in connection with this offering. These amounts are shown assuming both no exercise and full exercise of the underwriters’ over -allotmentoption.

|                                                   |    Per Unit(1) |                |          Total |                |
|                                                   |        Without 
 Over-allotment |           With 
 Over-allotment |        Without 
 Over-allotment |           With 
 Over-allotment |
| Underwriting discounts and commissions paid by us |          $0.60 |          $0.60 |    $10,500,000 |    $12,075,000 |

____________ (1)Includes (a) $0.15 per unit sold in the base offering, or $2,625,000, payable to the underwriters upon the closing of this offering and (b) $0.45 per unit sold in the base offering, or $7,875,000, for deferred underwriting commissions to be placed in a trust account located in the United States and released to UBS only upon the completion of an initial business combination. If the underwriters’ over -allotmentoption is exercised, $0.60 per over -allotmentunit, or up to an additional $1,575,000 (or $9,450,000 in the aggregate if the underwriters’ over -allotmentoption is exercised in full) will be placed in the trust account as deferred underwriting commissions and released to UBS only upon the completion of an initial business combination. If we do not complete our initial business combination within the completion window, the underwriters have agreed that (i) they will forfeit any rights or claims to their deferred underwriting discounts and